Non-Hormonal Menopause Treatments: Fezolinetant, SSRIs and What the Evidence Grades

The pharmacist slid the paper bag across the counter and said, almost as an aside, “This one isn’t a hormone.” The woman collecting it, who had turned down estrogen twice after a breast cancer scare in her forties, told me later that the sentence landed harder than anything her oncologist had said in a year.

That small exchange explains why fezolinetant is one of the most-searched menopause terms right now. As of January 2026, the drug has been on US pharmacy shelves for two and a half years, its label carries a liver warning added in late 2024, England’s health service has started prescribing it after a national cost-effectiveness review, and a second medicine in the same class, elinzanetant, won US approval in October 2025. Social feeds have taken all of this and compressed it into one tidy, misleading phrase: “hormone-free HRT.”

It is not that. What it actually is, how well it works next to antidepressant-type options, and what the trials can and cannot tell you, is a more interesting story.

What changed recently with fezolinetant and non-hormonal menopause care

Three dated events pushed this topic from specialist journals into kitchen-table conversation.

In May 2023 the US Food and Drug Administration approved fezolinetant for moderate to severe vasomotor symptoms caused by menopause. Vasomotor symptoms is the clinical umbrella for hot flashes and night sweats. It was the first drug in a new class, the neurokinin 3 receptor antagonists, and the first genuinely new mechanism for hot flashes in decades. The UK regulator followed in December 2023, and the European Commission authorized it the same month under the brand name Veoza.

In September 2024 the FDA announced a label change after post-marketing reports of serious liver injury, and by December 2024 the prescribing information carried a boxed warning, the agency’s most prominent safety alert, along with tighter instructions for liver blood tests. The MedlinePlus drug entry listed in our references reflects that update. This was not a withdrawal; it was a recalibration of who should take it and how closely they should be watched.

Then, in October 2025, the FDA approved elinzanetant, a related compound that blocks two neurokinin receptors rather than one. Having two approved drugs in a class tends to trigger a wave of comparison articles, pharmacy promotions and influencer commentary, which is exactly what happened.

Running underneath all of this is the 2023 position statement from The Menopause Society on non-hormone therapy, which graded the evidence for every popular option from cognitive behavioral therapy to black cohosh. Clinicians now have a tidy evidence ladder, and the public has started asking which rung each product sits on. That is the question the rest of this article tries to answer plainly.

How does fezolinetant work without hormones?

Think of the hypothalamus, a thumbnail-sized region at the base of the brain, as a thermostat. For most of adult life estrogen keeps a cluster of nerve cells there, called KNDy neurons, politely quiet. KNDy is simply shorthand for three chemical messengers those cells release: kisspeptin, neurokinin B and dynorphin.

When ovarian estrogen falls at menopause, the brake comes off. KNDy neurons swell, fire more often and flood nearby circuits with neurokinin B. The thermostat’s comfort zone narrows to a sliver, so a tiny rise in core temperature that would once have gone unnoticed now trips a full heat-dumping response: skin vessels dilate, sweat glands open, the heart speeds up. That is a hot flash, and the night-time version is what soaks the sheets.

Fezolinetant sits on the neurokinin 3 receptor, the docking site neurokinin B uses to deliver its message, and blocks it. The signal is still sent, but the receiving end is muffled. Estrogen is not replaced, and ovarian or uterine tissue is not stimulated, which is why the drug is classed as non-hormonal.

Two practical consequences follow from the mechanism. First, the effect is specific to the heat-regulation pathway; it does not address vaginal dryness, bone loss or other estrogen-dependent changes. Second, because the target is in the brain and the drug is cleared largely by a liver enzyme called CYP1A2, anything that blocks that enzyme can raise blood levels substantially. The antidepressant fluvoxamine is the clearest example and the label lists it as a contraindication. Your prescriber or pharmacist will screen for this interaction before you start.

Elinzanetant, the newer agent, additionally blocks the neurokinin 1 receptor, which researchers believe contributes its measurable effect on sleep. Fezolinetant’s sleep benefit in trials was present but more modest.

What the evidence actually says about fezolinetant, graded

Evidence comes in grades. Randomized controlled trials, in which participants are assigned by chance to drug or placebo, sit at the top because they cancel out the powerful placebo response that plagues hot-flash research. Observational studies, which simply watch what happens to people who chose a treatment, sit lower. Expert opinion sits lowest.

For fezolinetant, the evidence is Level I, meaning it rests on multiple well-run randomized trials. The pivotal studies were SKYLIGHT 1 and SKYLIGHT 2, each enrolling just over 500 women with at least seven moderate to severe hot flashes a day. Both ran a 12-week placebo-controlled phase followed by a 40-week extension. At week 12, women on the approved strength reported roughly 2.5 fewer hot flashes per day than women on placebo, with the drug group falling from about 11 episodes a day to around 4 or 5. Severity scores also dropped. The difference was statistically significant by week 4 and visible within the first week.

A third trial, SKYLIGHT 4, followed more than 1,800 women for 52 weeks primarily to check safety, including the lining of the uterus. It found no signal of endometrial thickening, which matters because that is the classic concern with estrogen-type drugs.

Where the evidence is thinner: trials excluded women with a history of breast cancer, so the label does not cover hot flashes triggered by tamoxifen or aromatase inhibitors, and separate studies in that group are still maturing. Participants were overwhelmingly in their mid-fifties, so data in women under 45 or over 65 are sparse. Nothing extends beyond one year of continuous use. And the liver injury cases that prompted the 2024 warning were rare enough that they did not surface in the trials themselves, a reminder that randomized studies are superb at measuring benefit and weaker at catching uncommon harm.

What are the common side effects of fezolinetant?

The honest headline is that most women in the trials tolerated the drug about as well as placebo, and the side effects that did stand out were unglamorous rather than alarming.

Across the SKYLIGHT program, the complaints reported more often with fezolinetant than placebo were abdominal pain, diarrhea, insomnia, back pain and, counterintuitively, hot flushes. That last one is an artifact: a woman whose flashes are not fully controlled may still log them as an adverse event. Rates for each were in the low single digits, typically 2 to 4 percent, and most were mild to moderate. Discontinuation because of side effects ran at roughly 3 to 5 percent, similar to placebo.

The side effect that earned its own warning is a rise in liver enzymes, specifically alanine aminotransferase (ALT), a protein that leaks into the blood when liver cells are irritated. In the trials about 2 percent of women had ALT climb to more than three times the upper limit of normal, compared with around 1 percent on placebo. The elevations were usually silent, were caught on scheduled blood tests, and reversed when the medicine was stopped. The post-marketing cases that drove the 2024 label change were more serious, with symptoms such as fatigue, nausea, pale stools, dark urine and yellowing of the skin or eyes, and they are why the current label calls for liver tests before starting, monthly for the first three months, and again at six and nine months.

What the trials did not show is as useful as what they did. No increase in blood clots, breast tenderness, headache beyond placebo levels, mood change or weight gain emerged, and uterine lining measurements stayed flat. Longer real-world experience is still accumulating, and the regulators’ adverse-event databases are the place where any new pattern would appear first. Any new symptom after starting should go to the prescriber, not to a search engine.

Fezolinetant and the liver: what the boxed warning does and does not mean

A boxed warning is the FDA’s way of saying “read this part even if you read nothing else.” It does not mean a drug is dangerous for most people; it means a specific, serious risk exists that patients and prescribers must plan around. Several widely used medicines carry one.

In fezolinetant’s case the risk is drug-induced liver injury. The FDA’s September 2024 safety communication described a patient who developed markedly raised liver enzymes and bilirubin along with jaundice-type symptoms about 40 days after starting, with recovery after stopping. Additional reports led to the boxed warning and to the current monitoring schedule.

The practical reading for a woman weighing the drug is this. Baseline liver blood tests are required, and the label advises against starting if those tests are already elevated or if there is known cirrhosis, the scarring stage of chronic liver disease. Severe kidney impairment is also listed as a reason not to use it. Regular blood draws during the first year are not optional extras; they are part of the treatment. And a short list of symptoms should prompt stopping and calling the clinic the same day: unusual fatigue, loss of appetite, nausea or vomiting, pain in the upper right abdomen, itching, pale stools, dark urine, or yellowing of the skin or eyes.

How common is serious injury? Rare enough that it did not appear in roughly 3,000 trial participants, which places it well below one in a thousand, but the true frequency cannot yet be stated with confidence. That uncertainty is itself a finding. When the evidence is incomplete, the mature response is monitoring rather than either panic or dismissal, and that is exactly what the label now asks for.

Does fezolinetant cause weight gain?

No signal of weight gain appeared in any of the fezolinetant trials, and weight change was not listed among the adverse reactions in the prescribing information. That is the direct answer, and it is grounded in randomized data from well over 2,000 women followed for up to a year.

Why, then, is this one of the most-typed questions about the drug? Partly because midlife weight gain is so common that almost any new medicine started between 45 and 60 will be blamed for it. Women gain on average about 1.5 pounds a year through the menopause transition, driven by age-related loss of muscle, lower activity and a shift of fat toward the abdomen as estrogen falls. A woman who starts a hot-flash medicine in March and weighs more in September has lived through six months of that background drift.

Partly, too, the question is borrowed from older treatments. Some antidepressants used for hot flashes, paroxetine in particular, can modestly increase weight over months. Gabapentin can cause fluid retention and appetite changes. Hormone therapy has its own reputation, although randomized trials have generally not shown it to add weight either. Fezolinetant has inherited the suspicion without the evidence.

There is a plausible indirect pathway worth naming honestly. Chronic night sweats fragment sleep, and poor sleep raises appetite hormones and lowers the energy for movement. A medicine that restores sleep could, in theory, nudge weight down rather than up. The trials did not measure this, so it remains a hypothesis, not a claim.

If weight changes noticeably after starting any new medicine, the useful move is to log it alongside sleep, appetite and activity and bring the record to the prescriber, who can separate drug effect from the ordinary physiology of midlife.

How does fezolinetant compare to HRT?

No randomized trial has pitted fezolinetant against menopausal hormone therapy head to head, so every comparison you read, including this one, is built from separate trials against placebo. That caveat matters, because placebo response varies between studies.

With that said, the pattern is consistent. Systemic estrogen, with progestogen added for women who have a uterus, remains the most effective treatment for hot flashes that exists. A Cochrane review of randomized trials found estrogen reduced hot-flash frequency by about 75 percent relative to placebo and severity by even more. Fezolinetant’s placebo-adjusted reduction in frequency sits closer to 20 to 25 percentage points, with total reductions of around 60 percent once the placebo effect is included. On the single outcome of fewer flashes, hormones win.

Hormone therapy also does things fezolinetant cannot. It treats vaginal dryness and painful intercourse, protects bone density, and in women who start within 10 years of their last period or before age 60, the balance of cardiovascular evidence is neutral to favorable. Fezolinetant addresses the thermostat and nothing else.

The comparison flips for women who cannot or will not take estrogen. Hormone therapy is generally avoided after estrogen-sensitive breast cancer, after a blood clot or stroke, with active liver disease or unexplained vaginal bleeding, and by many women who simply prefer not to. For them the relevant comparison is not fezolinetant versus HRT but fezolinetant versus SSRIs, gabapentin or nothing, and in that league it is the strongest option so far.

The choice is therefore not “which is better” but “which is appropriate for this woman, this history and these priorities.” Guidelines place that decision with the treating clinician, and a woman already on hormone therapy should not switch or stop on the strength of an article.

SSRIs and SNRIs for hot flashes: how strong is the evidence?

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are antidepressants that raise the availability of serotonin, or serotonin plus norepinephrine, in the brain. Both chemicals also help set the hypothalamic thermostat, which is why these drugs were tried for hot flashes long before anyone had heard of neurokinin.

The evidence is Level I, from more than a dozen randomized placebo-controlled trials, and the picture they paint is one of modest but real benefit. Paroxetine, venlafaxine, desvenlafaxine, escitalopram and citalopram have each reduced hot-flash frequency by roughly 50 to 65 percent, against a placebo response of around 30 to 40 percent. Expressed in daily counts, that is typically one to two fewer flashes per day than placebo, compared with fezolinetant’s two to three. The benefit usually appears within one to two weeks.

A low-strength formulation of paroxetine mesylate (Brisdelle) is the only antidepressant with FDA approval specifically for menopausal hot flashes, granted in 2013. The others are used off-label, meaning for a purpose outside the approved indication. That is legal, common and supported by guidelines, but it also means the decision and the counseling belong with the prescriber rather than with a patient reading trial abstracts.

Side effects are the trade-off: nausea in the first weeks, dry mouth, sleep disturbance, reduced libido or delayed orgasm, and for paroxetine a known interaction with tamoxifen, the breast cancer drug, because paroxetine blocks the enzyme that activates it. Stopping abruptly can cause dizziness and flu-like withdrawal symptoms, so any end to treatment is planned with the clinician.

For a woman whose hot flashes travel with low mood, anxiety or poor sleep, an SSRI or SNRI may treat two problems at once, which is a legitimate reason a clinician might reach for it first.

Other non hormonal menopause treatment options the guidelines actually endorse

The 2023 Menopause Society statement did something useful: it sorted every popular option into “recommended,” “not recommended,” and “insufficient evidence.” The recommended list is shorter than the supplement aisle would have you believe.

Cognitive behavioral therapy (CBT), a structured talking therapy that changes how a person interprets and reacts to symptoms, earned Level I evidence. In randomized trials it did not reduce the number of hot flashes much, but it substantially reduced how bothersome women found them and improved sleep and mood. The UK health service lists CBT alongside medicines in its menopause guidance.

Clinical hypnosis, delivered by a trained practitioner over several sessions, also reached Level I, with trials showing reductions in frequency and severity comparable to some medicines. Availability is the limiting factor.

Gabapentin, an anti-seizure medicine also used for nerve pain, reduces hot flashes by a margin similar to SSRIs and may be especially helpful for night sweats because drowsiness is its main side effect. Oxybutynin, a bladder medicine, has randomized data showing meaningful reductions, with dry mouth as the usual complaint and a question mark over long-term cognitive effects in older adults.

Weight loss in women carrying excess weight has Level II evidence for fewer flashes, and stellate ganglion block, an injection near a nerve bundle in the neck, has early randomized support but remains a specialist procedure.

The “not recommended” column is where the surprises live: soy isoflavones, black cohosh, evening primrose, cannabinoids, acupuncture, yoga, exercise programs, cooling gadgets and dietary changes all failed to beat placebo for hot flashes in controlled trials, even if several are worthwhile for general health. Clonidine, once a standard non-hormonal prescription, was dropped because its side effects outweigh a small benefit.

Fezolinetant vs SSRIs vs hormone therapy: a side-by-side summary

Numbers below are drawn from separate placebo-controlled trials rather than head-to-head studies, so treat them as orders of magnitude, not a league table. Evidence grades follow the convention used in the Menopause Society statement: Level I means multiple randomized trials, Level II means limited randomized or strong observational data.

Option	Typical reduction in hot-flash frequency vs placebo	Evidence grade	Main trade-offs	Also helps with
Systemic hormone therapy	Largest; around 75% relative reduction	Level I	Not suitable after estrogen-sensitive cancer or clots; needs progestogen if uterus present	Vaginal symptoms, bone density
Fezolinetant	About 2–3 fewer flashes per day; roughly 60% total reduction	Level I	Liver blood tests required; boxed warning; CYP1A2 interactions	Night sweats; modest sleep benefit
SSRIs / SNRIs	About 1–2 fewer flashes per day; roughly 50–65% total reduction	Level I	Nausea, sexual side effects, withdrawal if stopped abruptly; paroxetine interacts with tamoxifen	Mood, anxiety
Gabapentin	Similar to SSRIs	Level I	Drowsiness, dizziness	Night sweats, sleep
CBT or clinical hypnosis	Small change in count; large change in bother	Level I	Time, access to trained therapist	Sleep, mood, coping
Supplements (soy, black cohosh)	No consistent benefit over placebo	Not recommended	Variable quality; possible liver reports with black cohosh	None established

Two things jump out. Every option that works has a trade-off that a prescriber must weigh against a specific woman’s history. And the placebo response in hot-flash trials is enormous, often 30 to 40 percent, which is why a product’s own testimonials tell you almost nothing. The table is a conversation starter for an appointment, not a menu for self-selection.

Who is a candidate for fezolinetant and other non-hormonal options?

The clearest candidates are women whose hot flashes are frequent and disruptive, and for whom estrogen is either medically unwise or personally unwanted. That second group is larger than clinicians once assumed; surveys consistently find a substantial share of women decline hormones on principle, and guidelines now treat that preference as a valid starting point rather than a hurdle to argue past.

Medical reasons that tilt toward a non-hormonal route include a personal history of estrogen-sensitive breast or endometrial cancer, previous blood clot or stroke, certain inherited clotting disorders, active liver disease (which, importantly, also argues against fezolinetant), and unexplained vaginal bleeding until it has been evaluated. Migraine with aura and poorly controlled blood pressure prompt caution with some hormone formulations but not an automatic refusal.

The breast cancer situation deserves a plain statement. Hot flashes from tamoxifen or aromatase inhibitors can be severe, and these women have the greatest need for a non-hormonal answer. Fezolinetant’s trials excluded them, so its label does not cover that use. Trials in this population are in progress, and until they report, any prescription there is off-label and belongs to a shared decision between the oncology and menopause teams. SSRIs other than paroxetine, gabapentin, oxybutynin and CBT all have data in cancer survivors and are the better-evidenced choices today.

Fezolinetant is not appropriate with cirrhosis, severe kidney impairment, raised baseline liver tests, or alongside fluvoxamine and other strong CYP1A2 inhibitors. Women who smoke heavily may clear the drug faster, which the prescriber will factor in.

Finally, severity matters. A woman with two mild flashes a day may do best with CBT and sleep strategies; a woman soaking three nightgowns a night is the person the SKYLIGHT trials were designed around. Matching the intensity of treatment to the intensity of symptoms is the quiet skill at the heart of good menopause care.

How long can you stay on Veozah?

The label sets no maximum duration, and the longest controlled experience is 52 weeks. Beyond one year, the honest answer is that nobody has published data, which is different from saying it is unsafe.

Within that first year the picture is reassuring on the questions the trials were built to answer. Efficacy held steady from week 12 through week 52 without the fading effect that sometimes blunts antidepressants. No endometrial thickening appeared. Liver enzyme elevations clustered in the early months, which is why the monitoring schedule is front-loaded into the first three months with later checks at six and nine.

What happens when you stop is also worth knowing. In the extension studies, women who moved from drug to placebo saw hot flashes return toward baseline within a few weeks. There was no rebound beyond the original level and no withdrawal syndrome, which contrasts with SSRIs. In practical terms, fezolinetant manages the symptom while it is taken; it does not reset the thermostat permanently.

How long symptoms themselves last shapes the decision. The median duration of bothersome hot flashes across the menopause transition is around seven years, and roughly one woman in three still has them a decade after her last period. A woman who starts treatment at 51 may reasonably ask, at 54 or 55, whether the underlying symptoms have quietened enough to try a supervised pause. Many clinicians build such a review into the annual visit.

Regulators and the manufacturer continue to collect long-term safety data, and the label may change again as it does. The decision to continue, pause or stop belongs with the prescriber who can see your blood results, your symptom diary and your wider health. Stopping on your own because of something you read is the one choice this article actively discourages.

Common myths about fezolinetant and non-hormonal menopause treatment

Myth: Fezolinetant is “natural” or “hormone-free HRT.” It is a synthetic prescription medicine that blocks a brain receptor. It contains no hormones, and it is not a form of hormone replacement. Calling it HRT confuses two different mechanisms and invites people to expect bone or vaginal benefits it does not deliver.

Myth: It has been pulled from the market for liver damage. It has not. The FDA added a boxed warning and monitoring requirements in 2024; the drug remains approved in the US, UK and EU. A warning is a condition of use, not a recall.

Myth: Because it is not a hormone, it has no risks. The liver warning is the obvious rebuttal. Every medicine that reaches the brain has effects beyond its target, and “non-hormonal” describes the mechanism, not the safety profile.

Myth: Antidepressants for hot flashes mean your doctor thinks it is all in your head. SSRIs and SNRIs act on the same thermoregulatory circuitry fezolinetant does, by a different route. Their use for hot flashes rests on randomized trials in women without depression. The choice reflects pharmacology, not a judgment about mood.

Myth: Supplements are a safer non-hormonal option. Black cohosh, soy and evening primrose have not beaten placebo in controlled trials for hot flashes, and dietary supplements are not required to prove efficacy before sale. Black cohosh has its own scattering of liver injury reports. “Unregulated” is not a synonym for “gentle.”

Myth: You can judge whether a treatment works from online reviews. With placebo responses of 30 to 40 percent, a product that does nothing will still generate thousands of glowing testimonials. Only a controlled comparison separates signal from hope.

Myth: A woman already on hormone therapy should switch to be safe. No trial supports swapping an effective, tolerated treatment for a less effective one. Changes to any prescribed regimen are a conversation with the prescriber.

When to see a doctor about hot flashes or fezolinetant side effects

See a clinician before starting any prescription hot-flash treatment, because the first job is confirming that menopause is the cause. Thyroid overactivity, certain medicines, infections, low blood sugar, anxiety and, rarely, some tumors can all produce flushing and sweats. Hot flashes that begin before 40, or that come with unexplained weight loss, fever, palpitations at rest or a new lump anywhere, deserve evaluation rather than a symptom medicine.

Book a routine appointment if hot flashes or night sweats are waking you more than a couple of nights a week, affecting work or relationships, or if you have tried lifestyle measures for a few months without relief. Bring a two-week diary of frequency and severity; it shortens the conversation and gives a baseline to measure treatment against.

If you are taking fezolinetant, stop and contact the prescriber the same day for any of the following: yellowing of the skin or the whites of the eyes, dark or tea-colored urine, pale or clay-colored stools, pain or tenderness under the right ribs, persistent nausea or vomiting, unusual tiredness, loss of appetite, or widespread itching. These are the recognized signs of liver injury and are the reason the drug carries a boxed warning. Do not wait for the next scheduled blood test.

Seek urgent care for severe abdominal pain, confusion, or any allergic reaction such as facial swelling, hives or difficulty breathing.

If you are taking an SSRI or SNRI for hot flashes, report new or worsening low mood, agitation or thoughts of self-harm promptly, and never stop abruptly without guidance because of withdrawal effects.

Any vaginal bleeding more than a year after your last period is a reason to be seen regardless of what treatment you take. It is usually benign, but it needs assessment, and no hot-flash medicine should delay that.

Every decision described in this article, starting, continuing, switching or stopping, belongs with the clinician who knows your history and can order the tests the evidence requires.

Frequently asked questions

Does fezolinetant cause weight gain?

No weight gain signal appeared in the fezolinetant randomized trials, and weight change is not listed as an adverse reaction on the prescribing information. Midlife weight drift of roughly 1.5 pounds a year is common regardless of treatment, which is why a new medicine often takes the blame. If weight changes noticeably after starting, log it with sleep and appetite and raise it with the prescriber.

How long can you stay on Veozah?

The label sets no maximum, and controlled data extend to 52 weeks, during which benefit held steady and no uterine lining changes appeared. Beyond one year, published evidence does not yet exist. Hot flashes return toward baseline within weeks of stopping, without rebound or withdrawal. Most clinicians review the need annually; any decision to continue, pause or stop belongs with your prescriber.

What are the common side effects of fezolinetant?

The most frequently reported were abdominal pain, diarrhea, insomnia and back pain, each affecting around 2 to 4 percent of trial participants and usually mild. About 2 percent had liver enzyme elevations detected on blood tests. Rare serious liver injury reported after launch led to a boxed warning in 2024. Symptoms such as jaundice, dark urine or pale stools require stopping and same-day medical contact.

How does fezolinetant compare to HRT?

Hormone therapy remains more effective, reducing hot-flash frequency by about 75 percent versus roughly 20 to 25 percentage points over placebo for fezolinetant, and it also treats vaginal symptoms and protects bone. No head-to-head trial exists. Fezolinetant’s role is for women who cannot or prefer not to take estrogen, where it is currently the best-evidenced option. The choice rests with the treating clinician.

Is fezolinetant a hormone?

No. Fezolinetant is a synthetic medicine that blocks the neurokinin 3 receptor, a docking site in the hypothalamus that becomes overactive when estrogen falls. It does not contain or mimic estrogen, progesterone or any other hormone, and trials showed no effect on the uterine lining. The viral label “hormone-free HRT” is inaccurate; it is a non-hormonal treatment with a different mechanism and a narrower range of benefits.

What is the best non hormonal menopause treatment for hot flashes?

Among non-hormonal options, fezolinetant has the largest measured reduction in hot-flash frequency in randomized trials, followed by SSRIs, SNRIs, gabapentin and oxybutynin, all graded Level I. Cognitive behavioral therapy and clinical hypnosis reduce how bothersome flashes feel. “Best” depends on your health history, other symptoms and tolerance for side effects, so the ranking is a starting point for a clinician’s assessment, not a prescription.

Can breast cancer survivors take fezolinetant?

The pivotal trials excluded women with a history of breast cancer, so the approved label does not cover hot flashes caused by tamoxifen or aromatase inhibitors. Trials in that population are under way but had not changed the label as of early 2026. Better-evidenced options for survivors today include non-paroxetine SSRIs, venlafaxine, gabapentin, oxybutynin and CBT. Any decision should involve both the oncology and menopause teams.

Why does fezolinetant need liver blood tests?

About 2 percent of trial participants developed liver enzyme elevations, and rare cases of serious liver injury reported after approval led the FDA to add a boxed warning in 2024. Blood tests before starting rule out existing liver problems, and scheduled tests during the first nine months catch silent enzyme rises early, when stopping the drug allows recovery. Skipping these tests removes the main safety net.

Do SSRIs really work for hot flashes if you are not depressed?

Yes. More than a dozen randomized trials in women without depression show paroxetine, venlafaxine, desvenlafaxine, escitalopram and citalopram reduce hot flashes by roughly one to two per day beyond placebo. The effect comes from serotonin and norepinephrine’s role in the brain’s thermostat, not from treating mood. Only low-dose paroxetine is formally approved for this use; the others are prescribed off-label at the clinician’s judgment.

What is elinzanetant and how is it different from fezolinetant?

Elinzanetant, approved by the FDA in October 2025, blocks both neurokinin 1 and neurokinin 3 receptors, whereas fezolinetant blocks only neurokinin 3. In its OASIS trials it reduced hot flashes to a similar degree and showed a clearer improvement in sleep. Neither has been compared directly with the other in a randomized trial, so claims that one is superior rest on indirect comparison and expert opinion.

References

• MedlinePlus: Fezolinetant
• NHS: Menopause treatment
• Cleveland Clinic: Hot flashes

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.